Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.

Cancer research and treatment - 1 Oct 2022

Park Ji Soo, Shin Saeam, Lee Yoon Jung, Lee Seung-Tae, Nam Eun Ji, Han Jung Woo, Lee Sun Hwa, Kim Tae Il, Park Hyung Seok

Abstract excerpt

PURPOSE: The aim of the study was to evaluate the clinical implication of multigene panel testing of beyond BRCA genes in Korean patients with BRCA1/2 mutation-negative breast cancer. MATERIALS AND METHODS: Between 2016 and 2019, a total of 700 BRCA1/2 mutation-negative breast cancer patients received comprehensive multigene panel testing and genetic counseling. Among them, 347 patients completed a questionnaire...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Counseling

Share to Genetic Predisposition to Disease

Share to Mutation

Share to Republic of Korea

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34793666
DOI: 10.4143/crt.2021.978
PMCID: PMC9582472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.PMID 34793666Read ↗

Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing SuggestionsSemantic proximity Read ↗

Multi gene panel testing for hereditary breast cancer - is it ready to be used?Semantic proximity Read ↗

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Semantic proximity Read ↗

Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.Semantic proximity Read ↗

Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.Semantic proximity Read ↗

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSemantic proximity Read ↗

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.Semantic proximity Read ↗

Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.Semantic proximity Read ↗

Multigene germline testing usefulness instead of BRCA1/2 single screening in triple negative breast cancer cases.Semantic proximity Read ↗

Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.